Azenta Q3 revenue $173M (+4% YoY); non-GAAP EPS $0.16 beat; FY revenue guidance cut but EBITDA margin expansion raised

Azenta, Inc.

2024-Q3 EPS reported -$2.90 revenue$486,260,000

Q3 revenue $173M, up 4% YoY, organic growth 5%. Sample Mgmt Solutions $81M (+7%), Multiomics $64M (flat), B Medical $29M (+7%).
GAAP diluted EPS from continuing ops -$0.12; non-GAAP diluted EPS $0.16 vs $0.13 prior year. Adjusted EBITDA $18M, margin 10.3% (+260bps YoY).
FY2024 revenue guidance lowered to $652-658M (organic down 1-2%); adjusted EBITDA margin expansion ~300bps; non-GAAP EPS guidance raised to $0.30-$0.36.
Repurchased 4.2M shares for $225.9M in Q3; expects to complete remaining $1.5B authorization by Oct 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.